Boston Scientific signs agreement to divest BTG Specialty Pharmaceuticals business

波士顿科学公司签署协议剥离BTG专业制药业务

2020-12-03 10:44:24 PHARMACEUTICAL

本文共609个字,阅读需2分钟

SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases. “This transaction will help the BTG Specialty Pharmaceuticals business enhance its potential as a fully integrated specialty pharmaceuticals platform,” said Anthony Higham, president, BTG, Specialty Pharmaceuticals. “We believe our capabilities and portfolio strongly complement those of SERB, and we look forward to this next chapter as we continue to positively impact the lives of patients and the people who care for them.” The BTG Specialty Pharmaceuticals business develops, manufactures and commercializes life-saving antidotes used in hospitals and emergency care settings, including the clinically proven and leading products CroFab®, DigiFab®, and Voraxaze®. The three franchises are expected to generate approximately $210 million in revenue for the full year 2020. “After acquiring BTG in 2019 for approximately $3.7 billion net of cash on hand, and following the close of this transaction, we will have divested the two BTG non-medical device portions – Pharmaceutical Licensing royalties in the fourth quarter of 2019 and Specialty Pharmaceuticals announced today – for more than $1.0 billion in net proceeds,” said Jeff Mirviss, executive vice president and president, Peripheral Interventions, Boston Scientific. “We continue to be very pleased with the performance of the core Interventional Medicines business, the primary driver of the BTG acquisition, which has delivered strong growth and is expected to exceed our original goal of $175 million in synergies.” The agreement includes the transfer of five facilities and approximately 280 employees globally. The transaction is expected to close in the first half of 2021, subject to customary regulatory approvals and other closing conditions. Source: Company Press Release
自2017年以来,Serib得到了私募股权公司Charterhouse Capital Partners的支持,该公司拥有多元化的处方药组合,主要针对罕见和危及生命的疾病。 BTG特种制药公司总裁Anthony Higham说:“这项交易将帮助BTG特种制药公司增强其作为一个完全整合的特种制药平台的潜力。我们相信,我们的能力和产品组合有力地补充了Serib公司的能力和产品组合,我们期待着下一个篇章的到来,因为我们将继续积极地影响患者和护理他们的人们的生活。“ BTG特种制药公司开发,制造和商业化用于医院和紧急护理机构的救生解毒剂,包括经临床验证的领先产品Crofab®,Digifab®和Voraxaze®。预计这三个专营权在2020年全年将产生约2.1亿美元的收入。 波士顿科学公司执行副总裁兼外围干预部总裁杰夫·米尔维斯说:“在2019年以约37亿美元的现金净额收购BTG之后,在交易完成之后,我们将以超过10亿美元的净收益剥离BTG的两个非医疗设备部分--2019年第四季度的药品许可使用费和今天宣布的特种制药。”我们继续对核心介入药物业务的表现感到非常高兴,该业务是收购BTG的主要推动力,它带来了强劲的增长,预计将超过我们最初的1.75亿美元的协同效应目标。“ 该协议包括在全球转让五家设施和约280名员工。交易预计将于2021年上半年完成,但须符合惯常的监管批准及其他成交条件。 来源:公司新闻稿

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文